Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation

Cancer Research

Volumn 71, Issue 23, 2011, Pages 7198-7206

  Acquaviva, Jaime ^a   Jun, Hyun G ^a   Lessard, Julie ^a   Ruiz, Rolando ^b   Zhu, Haihao ^a   Donovan, Melissa ^b   Woolfenden, Steve ^a   Boskovitz, Abraham ^b   Raval, Ami ^b   Bronson, Roderick T ^c   Pfannl, Rolf ^b   Whittaker, Charles A ^d   Housman, David E ^d   Charest, Al ^a,b,d  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; BIM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GENETICS; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CHEMOSENSITIVITY; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; LIGANDS; MEMBRANE PROTEINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 82655181476     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1514     Document Type: Article

References (50)

1. Brennan C. Genomic profiles of glioma. Curr Neurol Neurosci Rep 2011;11:291-7.
2. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-710. (Pubitemid 350070717)
3. Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal 2009;2:re6.
4. The Cancer Genome Atlas [homepage on the Internet]. Available from: http://cancergenome.nih.gov [cited October 3, 2011].
5. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis M, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
6. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, WilkersonMD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
7. Attolini CS, Cheng YK, Beroukhim R, Getz G, Abdel-Wahab O, Levine RL, et al. A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A 2010;107:17604-9.
8. Tang P, Steck PA, Yung WK. The autocrine loop of TGF-alpha/EGFR and brain tumors. J Neurooncol 1997;35:303-14. (Pubitemid 27511133)
9. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991;51:2164-72.
10. Mishima K, Higashiyama S, Asai A, Yamaoka K, Nagashima Y, Taniguchi N, et al. Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta Neuropathol 1998;96:322-8. (Pubitemid 28451136)
11. Schlegel U, Moots PL, Rosenblum MK, Thaler HT, Furneaux HM. Expression of transforming growth factor alpha in human gliomas. Oncogene 1990;5:1839-42. (Pubitemid 120034712)
12. Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002;297:63-4. (Pubitemid 34743088)
13. Sharma SV, Settleman J. Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock". Biochem Pharmacol 2010;80:666-73.
14. Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, et al. The plasticity of oncogene addiction: implications for targetedtherapies directed to receptor tyrosine kinases. Neoplasia 2009;11:448-58, 2 p following 458.
15. Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 2009;6:500-12.
16. Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2007;13:378-81. (Pubitemid 46225339)
17. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24. (Pubitemid 41609094)
18. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 2008;26:5603-9.
19. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009;27:1268-74.
20. Hambardzumyan D, Parada LF, Holland EC, Charest A. Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia 2011;59:1155-68.
21. Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R, et al. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A 2009;106:2712-6.
22. Maruno M, Kovach JS, Kelly PJ, Yanagihara T. Transforming growth factor-alpha, epidermal growth factor receptor, and proliferating potential in benign and malignant gliomas. J Neurosurg 1991;75:97-102.
23. Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, et al. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 2006;66:867-74. (Pubitemid 43165952)
24. Samuels V, Barrett JM, Bockman S, Pantazis CG, Allen MB Jr. Immunocytochemical study of transforming growth factor expression in benign and malignant gliomas. Am J Pathol 1989;134:894-902.
25. van der Valk P, Lindeman J, Kamphorst W. Growth factor profiles of human gliomas. Do non-tumour cells contribute to tumour growth in glioma? Ann Oncol 1997;8:1023-9. (Pubitemid 27475735)
26. Yung WK, Zhang X, Steck PA, Hung MC. Differential amplification of the TGF-alpha gene in human gliomas. Cancer Commun 1990;2:201-5. (Pubitemid 20335655)
27. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007;4:1669-79; discussion 1680.
28. Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, et al. ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBOJ 2007;26:2856-67. (Pubitemid 46975775)
29. Ewings KE, Wiggins CM, Cook SJ. Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels. Cell Cycle 2007;6:2236-40. (Pubitemid 47547699)
30. Ciardiello F, McGeady ML, Kim N, Basolo F, Hynes N, Langton BC, et al. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation. Cell Growth Differ 1990;1:407-20.
31. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 1987;51:1063-70.
32. Di Marco E, Pierce JH, Aaronson SA, Di Fiore PP. Mechanisms by which EGF receptor and TGF alpha contribute to malignant transformation. Nat Immun Cell Growth Regul 1990;9:209-21. (Pubitemid 20304035)
33. Di Marco E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson SA, et al. Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 1989;4:831-8. (Pubitemid 19176969)
34. Rosenthal A, Lindquist PB, Bringman TS, Goeddel DV, Derynck R. Expression in rat fibroblasts of a human transforming growth factoralpha cDNA results in transformation. Cell 1986;46:301-9. (Pubitemid 16031692)
35. Shankar V, Ciardiello F, Kim N, Derynck R, Liscia DS, Merlo G, et al. Transformation of an established mouse mammary epithelial cell line following transfection with a human transforming growth factor alpha cDNA. Mol Carcinog 1989;2:1-11. (Pubitemid 19148369)
36. Watanabe S, Lazar E, Sporn MB. Transformation of normal rat kidney (NRK) cells by an infectious retrovirus carrying a synthetic rat type alpha transforming growth factor gene. Proc Natl Acad Sci U S A 1987;84:1258-62. (Pubitemid 17027332)
37. Andl CD, Mizushima T, Nakagawa H, Oyama K, Harada H, Chruma K, et al. Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem 2003;278:1824-30. (Pubitemid 36801419)
38. Cheng J, Huang H, Zhang ZT, Shapiro E, Pellicer A, Sun TT, et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res 2002;62:4157-63. (Pubitemid 34791088)
39. Ding H, Shannon P, Lau N, Wu X, Roncari L, Baldwin RL, et al. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res 2003;63:1106-13. (Pubitemid 36278445)
40. Iyer AK, Tran KT, Griffith L, Wells A. Cell surface restriction ofEGFRby a tenascin cytotactin-encoded EGF-like repeat is preferential for motility-related signaling. J Cell Physiol 2008;214:504-12. (Pubitemid 350309007)
41. Lipeski LE, Boylan JM, Gruppuso PA. A comparison of epidermal growth factor receptor-mediated mitogenic signaling in response to transforming growth factor alpha and epidermal growth factor in cultured fetal rat hepatocytes. Biochem Mol Biol Int 1996;39:975-83. (Pubitemid 26290288)
42. Inda MM,Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010;24:1731-45.
43. Scott JD, Pawson T. Cell signaling in space and time: where proteins come together and when they're apart. Science 2009;326:1220-4.
44. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005;1:2005.0010.
45. Agazie YM, Hayman MJ. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol Cell Biol 2003;23:7875-86. (Pubitemid 37271483)
46. Rotin D, Margolis B, Mohammadi M, Daly RJ, Daum G, Li N, et al. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma. EMBO J 1992;11:559-67.
47. Tamas P, Solti Z, Bauer P, Illes A, Sipeki S, Bauer A, et al. Mechanism of epidermal growth factor regulation of Vav2, a guanine nucleotide exchange factor for Rac. J Biol Chem 2003;278:5163-71. (Pubitemid 36801028)
48. Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 2008;18:73-9. (Pubitemid 351694445)
49. Faber AC, Wong KK, Engelman JA. Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 2010;9:851-2.
50. Shimshek DR, Kim J, Hubner MR, Spergel DJ, Buchholz F, Casanova E, et al. Codon-improved Cre recombinase (iCre) expression in the mouse. Genesis 2002;32:19-26. (Pubitemid 34117128)